Nom | Support | Langue | Disponibilité | Date d'édition | Prix | ||
---|---|---|---|---|---|---|---|
Papier |
Anglais |
Disponible |
05/05/2022 |
18,00 € |
|
Détails
Since their clinical use initiation in the 1970’s, Fluorine-18 (F-18) radiopharmaceuticals continue to play an important role in nuclear medicine. It is therefore essential to make available broad information on practical production routes and optimal quality control for F- 18 tracers, to achieve the best possible products in high quantity and quality for clinical applications while fulfilling all regulatory requirements. This publication describes the chemical and biological properties of F-18 radiopharmaceuticals. This includes aspects relating to F-18 target production and radiofluorination methods, with focus on the applied techniques. The publication presents a disease oriented approach, describing F-18 radiopharmaceuticals, ranging from the physiological/biological aspects to dedicated radiopharmaceutical development approaches and provides readers with clear guidelines and methods for the production of F-18 radiopharmaceuticals.
Informations supplémentaires
Auteur | International Atomic Energy Agency (IAEA) |
---|---|
Edité par | IAEA |
Couverture | Paperback |
Type de document | Livre |
Thème | Nuclear medicine (including radiopharmaceuticals) |
Edition révision n° | 2021 |
Nombre de pages | 166 |
Poids (kg.) | 0.47 |
Mot-clé | IAEA-TECDOC-1968,Nuclear medicine (including radiopharmaceuticals) |